Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Pareto8020on Sep 06, 2021 10:23am
416 Views
Post# 33816446

Time = Now

Time = NowSBM/Howard - you've had enough time - now you need to actually accomplish one of the milestones you were kidding around about completing back in May....then July.  Here we are back to school and work and it is time to deliver not be radio silent as usual.  

After 7 years+ you should have the Phase I results - grow a pair and get the info off your "partner" Wanbang. 

Or how about signing a contract to put SBM into a "new era" as per your interview in May 2021: 

 https://www.cafepharma.com/cpwire/article/Sirona-Biochems-Innovations-in-Biotechnology-Lead-to-Safer-More-Effective-Cosmetic-and-Pharmaceutical-Active-Ingredients-/404403-


Sirona is working intensively towards achieving the following milestones:*
• Establish terms with global pharma company for rights to TFC-1067
• Establish terms with new organization in China for TFC-1067
• Receive terms for additional licensing agreement for the SGLT2 inhibitor in new markets
• Secure non-dilutive funding through anticipated collaborations
• Receive feedback on analysis from Phase I (from Wanbang) for the SGLT2 inhibitor
• Complete safety studies for anti-aging compound in preparation for clinical study • Establish detailed project plan for scale-up and clinical trial
• Enter clinical trial for anti-wrinkle compound • Advance the anti-viral compounds into preclinical studies
<< Previous
Bullboard Posts
Next >>